Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS21 JULY 2021 at 3:45 p.m. EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds decreased on 20 July 2021 below five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification:   % of shares and voting rights (total of point A) % of shares and voting rights through financial instruments (total of point B) Total of both in % (points A + B) Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached 4.99% shares   Below 5% voting rights 0.04% shares   Below 5% voting rights 5.03% shares   Below 5% voting rights 141,134,278 shares   806,258,215 voting rights Position of previous notification (if applicable) 5.00% shares   Below 5% voting rights 0.04% shares   Below 5% voting rights 5.05% shares   Below 5% voting rights   Notified details of the resulting situation on the date on which the threshold was crossed: Point A: Shares and voting rights: Class/type of sharesISIN code Number of shares and voting rights % of shares and voting rights   Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) FI0009014377   7,049,433 shares   Below 5% voting rights   4.99% shares   Below 5% voting rights POINT A SUBTOTAL 7,049,433 shares       Below 5% voting rights 4.99% shares   Below 5% voting rights Point B: Financial instruments according to SMA 9:6a: Type of financial instrument Expiration date Exercise / Conversion Period Physical or cash settlement Number of shares and voting rights % of shares and voting rights Securities Lent N/A N/A Physical 45,859 shares   Below 5% voting rights 0.03% shares   Below 5% voting rights CFD N/A N/A Cash 15,527 shares   Below 5% voting rights 0.01% shares   Below 5% voting rights       POINT B SUBTOTAL 61,386 shares   Below 5% voting rights 0.04% shares   Below 5% voting rights Orion Corporation Timo Lappalainen President and CEO     Olli Huotari SVP, Corporate Functions                                                   Contact person:Terhi Ormio, VP, Communications, Orion Corporationtel. +358 10 426 4646  Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.